Novel Drug for HER2-Mutant Lung Cancer Wins FDA Approval
Zongertinib induced responses in 75% of mutation carriers with non-squamous NSCLC
Related Articles
Telemedicine Boosts Abortion Access in Restrictive Rural Areas
Asynchronous telemedicine medication abortion has filled some care gaps post-Roe
In Utero Treatment for Brain Birth Defect Feasible, Promising
First seven attempts appeared to have improved mortality, morbidity of congenital condition
Nurses as Vital Partners in the Fight Against Antimicrobial Resistance – AJN Off the Charts
Nurses are integral to antimicrobial stewardship. Their roles in monitoring, administration, specimen collection, education, and multidisciplinary collaboration ensure safer, more effective antibiotic use. With strong…
‘Clear’ Vapes May Have Even Worse Health Effects
Products put flavorings in a gray area amid state restrictions
Could a Conch Shell Be a Competitor for CPAP?
Proof-of-concept trial shows significant effect on obstructive sleep apnea symptoms
Upfront Genetic Testing in GI Cancers May Lower Chemo Toxicity Risk
Gene-based adjustments appear to reduce toxic effects, discontinuations versus standard dosing
No Gym Needed for Pulmonary Rehab, Study Says
Trial shows simpler, minimal equipment version is just as good
Popular Diabetes Drugs Linked to Small Risk of Retinal, Optic Nerve Disorders
Screening, monitoring for eye disease urged for all patients on semaglutide, tirzepatide
Aluminum in Vaccines Study Won’t Be Retracted, Journal Says
Large Danish study evaluated risks of autism, asthma, and other disorders in 1.2 million children
Prophylactic Antibiotics May Be of No Use in Cirrhosis With Upper GI Bleeding
Findings contradict current guidelines, suggesting a need for new randomized trials
